Welcome to our dedicated page for Teva Pharm SEC filings (Ticker: TEVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Teva Pharmaceutical Industries Limited (TEVA) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the Securities and Exchange Commission. As an issuer with American Depositary Shares listed on the New York Stock Exchange under the symbol TEVA, Teva reports material events, financing arrangements and financial results through these filings.
Recent Form 8‑K filings include items on results of operations and financial condition, where Teva furnishes press releases announcing quarterly financial results for periods such as the quarters ended June 30 and September 30. These filings typically incorporate earnings press releases by reference and clarify that the information is being furnished rather than filed for purposes of the Exchange Act. Another 8‑K describes Teva’s presentation at a major healthcare conference and includes expectations regarding performance for the 2025 fiscal year.
Teva also uses Form 8‑K to disclose material definitive agreements and related direct financial obligations. For example, an 8‑K details the Third Amendment to the Senior Unsecured Sustainability-Linked Revolving Credit Agreement, which extended the maturity date of the revolving facility and amended financial covenants such as the maximum leverage ratio and conditions tied to investment grade status. These filings provide insight into Teva’s capital structure, liquidity management and covenant framework.
On Stock Titan, investors can review these filings alongside AI-powered summaries that explain the main points of each document in plain language. This includes highlighting key terms in credit agreements, summarizing earnings-related disclosures, and pointing out items that may affect leverage, liquidity or future reporting. Users interested in TEVA can use the filings page to track quarterly and annual reporting, current reports on material events, and disclosures related to financing arrangements, while AI tools help interpret lengthy or technical sections of the filings.
TEVA PHARMACEUTICAL INDUSTRIES LTD officer Mark Sabag completed an open-market sale of 144,180 Ordinary Shares on May 1, 2026, at a weighted average price of $34.9918 per share. Following this sale, he directly holds 80,760 Ordinary Shares, which may be represented by American Depositary Shares on a one-for-one basis.
Teva Pharmaceutical Industries EVP Christine Fox, who leads U.S. Commercial operations, reported an open-market sale of 21,258 Ordinary Shares of Teva on April 30, 2026 at a weighted average price of $35.31 per share. The filing notes these shares were sold in multiple trades between $35.28 and $35.33 per share. Following this transaction, Fox directly holds 63,647 Ordinary Shares, which may also be represented by American Depositary Shares, each currently representing one Ordinary Share.
Teva Pharmaceutical Industries Limited submitted a Form 144 notice reporting proposed sales of ordinary shares by holders, including 110,668 and 33,512 shares described as "shares from rollover" and compensation-related sales. The filing lists a prior sale of 62,102 shares on 03/17/2026 with a reported value of 1,871,815.26.
Teva Pharmaceutical Industries submitted a Form 144 notice reporting proposed sales tied to recent vesting of stock awards. The filing lists vesting events on 03/04/2026 (11,363 shares) and 03/05/2026 (9,895 shares). It records two dispositions by Christine Fox: 9,908 shares on 03/04/2026 for $321,658.26 and 7,924 shares on 03/05/2026 for $250,940.40.
Teva Pharmaceutical Industries Limited reported another profitable quarter with net revenues of $3,982 million for the three months ended March 31, 2026, up slightly from $3,891 million a year earlier, as stronger gross profit more than offset higher selling and marketing costs.
Net income attributable to Teva rose to $369 million from $214 million, and diluted earnings per share increased to $0.31 from $0.18. Operating income improved to $652 million, helped by much lower intangible asset impairments compared with the prior year.
Cash and cash equivalents increased to $3,741 million while net cash used in operating activities was $40 million, influenced by a $617 million net use of cash in working capital. Total assets were $40,040 million and total equity rose to $8,232 million.
Teva continued to adjust its portfolio and capital structure. Senior notes and loans decreased to $14,015 million, and assets held for sale of $1,794 million mainly related to the API business remain classified for divestiture. Legal provisions for settlements and loss contingencies totaled $4,680 million, with $72 million of related expenses recorded this quarter.
Strategic R&D and funding transactions advanced the pipeline. Teva agreed to acquire Emalex Biosciences for $700 million plus up to $200 million in milestones, and entered funding agreements with Blackstone Life Sciences and Royalty Pharma that could provide up to $900 million across key late-stage programs. Several collaboration partners, including Sanofi, Alvotech, MedinCell and others, progressed Phase 3 or registration-stage assets, supporting Teva’s Pivot to Growth strategy.
Teva Pharmaceutical Industries Limited reported another profitable quarter with net revenues of $3,982 million for the three months ended March 31, 2026, up slightly from $3,891 million a year earlier, as stronger gross profit more than offset higher selling and marketing costs.
Net income attributable to Teva rose to $369 million from $214 million, and diluted earnings per share increased to $0.31 from $0.18. Operating income improved to $652 million, helped by much lower intangible asset impairments compared with the prior year.
Cash and cash equivalents increased to $3,741 million while net cash used in operating activities was $40 million, influenced by a $617 million net use of cash in working capital. Total assets were $40,040 million and total equity rose to $8,232 million.
Teva continued to adjust its portfolio and capital structure. Senior notes and loans decreased to $14,015 million, and assets held for sale of $1,794 million mainly related to the API business remain classified for divestiture. Legal provisions for settlements and loss contingencies totaled $4,680 million, with $72 million of related expenses recorded this quarter.
Strategic R&D and funding transactions advanced the pipeline. Teva agreed to acquire Emalex Biosciences for $700 million plus up to $200 million in milestones, and entered funding agreements with Blackstone Life Sciences and Royalty Pharma that could provide up to $900 million across key late-stage programs. Several collaboration partners, including Sanofi, Alvotech, MedinCell and others, progressed Phase 3 or registration-stage assets, supporting Teva’s Pivot to Growth strategy.
Teva Pharmaceutical Industries Limited reported another profitable quarter with net revenues of $3,982 million for the three months ended March 31, 2026, up slightly from $3,891 million a year earlier, as stronger gross profit more than offset higher selling and marketing costs.
Net income attributable to Teva rose to $369 million from $214 million, and diluted earnings per share increased to $0.31 from $0.18. Operating income improved to $652 million, helped by much lower intangible asset impairments compared with the prior year.
Cash and cash equivalents increased to $3,741 million while net cash used in operating activities was $40 million, influenced by a $617 million net use of cash in working capital. Total assets were $40,040 million and total equity rose to $8,232 million.
Teva continued to adjust its portfolio and capital structure. Senior notes and loans decreased to $14,015 million, and assets held for sale of $1,794 million mainly related to the API business remain classified for divestiture. Legal provisions for settlements and loss contingencies totaled $4,680 million, with $72 million of related expenses recorded this quarter.
Strategic R&D and funding transactions advanced the pipeline. Teva agreed to acquire Emalex Biosciences for $700 million plus up to $200 million in milestones, and entered funding agreements with Blackstone Life Sciences and Royalty Pharma that could provide up to $900 million across key late-stage programs. Several collaboration partners, including Sanofi, Alvotech, MedinCell and others, progressed Phase 3 or registration-stage assets, supporting Teva’s Pivot to Growth strategy.
Teva Pharmaceutical Industries reported first quarter 2026 revenues of $3.98 billion, up 2% in U.S. dollars but down 3% in local currencies, as strong growth in key innovative brands offset weaker generics, especially lower U.S. sales of lenalidomide capsules.
GAAP diluted EPS rose to $0.31 from $0.18, while non-GAAP diluted EPS edged up to $0.53 from $0.52, supported by higher gross profit and lower intangible impairments. Innovative products AUSTEDO, AJOVY and UZEDY generated $838 million collectively and grew 41% year over year in local currency.
Teva maintained its 2026 outlook, guiding to revenues of $16.4–$16.8 billion, non-GAAP operating income of $3.8–$4.0 billion and free cash flow of $2.0–$2.4 billion, including the impact of its agreement to acquire Emalex Biosciences for $700 million upfront plus up to $200 million in milestones and royalties tied to ecopipam for pediatric Tourette syndrome.
Teva Pharmaceutical Industries reported first quarter 2026 revenues of $3.98 billion, up 2% in U.S. dollars but down 3% in local currencies, as strong growth in key innovative brands offset weaker generics, especially lower U.S. sales of lenalidomide capsules.
GAAP diluted EPS rose to $0.31 from $0.18, while non-GAAP diluted EPS edged up to $0.53 from $0.52, supported by higher gross profit and lower intangible impairments. Innovative products AUSTEDO, AJOVY and UZEDY generated $838 million collectively and grew 41% year over year in local currency.
Teva maintained its 2026 outlook, guiding to revenues of $16.4–$16.8 billion, non-GAAP operating income of $3.8–$4.0 billion and free cash flow of $2.0–$2.4 billion, including the impact of its agreement to acquire Emalex Biosciences for $700 million upfront plus up to $200 million in milestones and royalties tied to ecopipam for pediatric Tourette syndrome.
Teva Pharmaceutical Industries reported first quarter 2026 revenues of $3.98 billion, up 2% in U.S. dollars but down 3% in local currencies, as strong growth in key innovative brands offset weaker generics, especially lower U.S. sales of lenalidomide capsules.
GAAP diluted EPS rose to $0.31 from $0.18, while non-GAAP diluted EPS edged up to $0.53 from $0.52, supported by higher gross profit and lower intangible impairments. Innovative products AUSTEDO, AJOVY and UZEDY generated $838 million collectively and grew 41% year over year in local currency.
Teva maintained its 2026 outlook, guiding to revenues of $16.4–$16.8 billion, non-GAAP operating income of $3.8–$4.0 billion and free cash flow of $2.0–$2.4 billion, including the impact of its agreement to acquire Emalex Biosciences for $700 million upfront plus up to $200 million in milestones and royalties tied to ecopipam for pediatric Tourette syndrome.
Teva Pharmaceutical Industries Ltd. is asking shareholders to reappoint Dr. Sol J. Barer as director through 2029, approve executive pay on an advisory basis, and ratify Kesselman & Kesselman (PwC network) as auditor through the 2027 meeting. The Board highlights progress on its “Pivot to Growth” strategy, emphasizing double‑digit growth for key innovative drugs AUSTEDO, UZEDY (including an FDA indication expansion for Bipolar I disorder) and AJOVY, as well as advancement of late‑stage assets like olanzapine LAI and duvakitug, which generated a $500 million Phase 3 milestone payment recorded as 2025 revenue. Teva reports 2025 global revenue growth in local currency, continued net debt reduction, and a stronger balance sheet supported by sustainable finance, including about $7.5 billion of sustainability‑linked bonds and a $1.8 billion sustainability‑linked revolving credit facility. The proxy details Board composition, committee structure, AI and cybersecurity oversight, human capital initiatives for Teva’s 33,950 employees, and an executive compensation framework heavily weighted to variable, performance‑based pay, alongside strengthened stock‑ownership guidelines and no hedging or repricing of underwater options.
Teva Pharmaceutical Industries officer Mark Sabag reported an open-market sale of 62,102 Ordinary Shares on March 17, 2026. The shares were sold at a weighted average price of $30.141 per share, in multiple trades between $30.115 and $30.215.
Following this transaction, Sabag directly owns 224,940 Ordinary Shares. The filing notes that each Ordinary Share may be represented by an American Depositary Share, with each ADS currently corresponding to one Ordinary Share.
Teva Pharmaceutical Industries officer Mark Sabag reported an open-market sale of 62,102 Ordinary Shares on March 17, 2026. The shares were sold at a weighted average price of $30.141 per share, in multiple trades between $30.115 and $30.215.
Following this transaction, Sabag directly owns 224,940 Ordinary Shares. The filing notes that each Ordinary Share may be represented by an American Depositary Share, with each ADS currently corresponding to one Ordinary Share.
Teva Pharmaceutical Industries reported a Form 144 notification for the proposed sale of 62,102 ordinary shares, listed for sale through Citigroup Global Markets Inc. on the NYSE. The shares are identified as rollover/compensation ordinary shares with trade dates listed in March 2026.